David S. Schade

8.6k total citations · 1 hit paper
184 papers, 5.3k citations indexed

About

David S. Schade is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Physiology. According to data from OpenAlex, David S. Schade has authored 184 papers receiving a total of 5.3k indexed citations (citations by other indexed papers that have themselves been cited), including 117 papers in Endocrinology, Diabetes and Metabolism, 61 papers in Surgery and 43 papers in Physiology. Recurrent topics in David S. Schade's work include Diabetes Management and Research (64 papers), Diet and metabolism studies (39 papers) and Pancreatic function and diabetes (37 papers). David S. Schade is often cited by papers focused on Diabetes Management and Research (64 papers), Diet and metabolism studies (39 papers) and Pancreatic function and diabetes (37 papers). David S. Schade collaborates with scholars based in United States, Canada and Australia. David S. Schade's co-authors include R. Philip Eaton, Mary F. Carroll, Richard C. Allen, Mark R. Burge, R. Philip Eaton, J C Standefer, Kathryn Erickson, Jill P. Crandall, W. J. Spencer and Andrew J. Krentz and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

David S. Schade

179 papers receiving 5.0k citations

Hit Papers

Long-term Metformin Use and Vitamin B12 Deficiency in the... 2016 2026 2019 2022 2016 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study
    2016 309 citations Trevor J. Orchard, David S. Schade et al. The Journal of Clinical Endocrinology & Metabolism profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David S. Schade United States 42 3.0k 1.4k 1.2k 972 917 184 5.3k
G. Perriello Italy 40 2.9k 1.0× 1.5k 1.1× 1.4k 1.2× 1.4k 1.5× 757 0.8× 87 5.1k
Graydon S. Meneilly Canada 42 3.1k 1.0× 1.4k 1.0× 1.5k 1.2× 1.0k 1.0× 592 0.6× 136 5.5k
Rudolf Prager Austria 38 2.5k 0.8× 1.4k 1.0× 1.2k 1.0× 1.2k 1.2× 543 0.6× 140 5.4k
Robert Sherwin United States 25 4.1k 1.4× 1.5k 1.1× 1.0k 0.9× 1.8k 1.9× 613 0.7× 44 6.2k
A H Barnett United Kingdom 32 2.0k 0.7× 877 0.6× 576 0.5× 776 0.8× 1.1k 1.2× 110 4.2k
Marilyn Ader United States 33 2.2k 0.7× 1.1k 0.8× 1.8k 1.5× 1.4k 1.4× 544 0.6× 50 4.8k
Antonio E. Pontiroli Italy 42 2.3k 0.8× 2.3k 1.7× 1.6k 1.3× 960 1.0× 571 0.6× 217 5.9k
Annunziata Lapolla Italy 42 2.6k 0.9× 1.1k 0.8× 827 0.7× 1.2k 1.2× 509 0.6× 253 6.4k
Marc Rendell United States 39 3.4k 1.1× 1.4k 1.0× 1.2k 1.0× 2.0k 2.0× 494 0.5× 154 6.2k
Stephen D. Luzio United Kingdom 33 2.5k 0.8× 1.2k 0.9× 551 0.5× 837 0.9× 752 0.8× 175 4.6k

Countries citing papers authored by David S. Schade

Since Specialization
Citations

This map shows the geographic impact of David S. Schade's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David S. Schade with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David S. Schade more than expected).

Fields of papers citing papers by David S. Schade

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David S. Schade. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David S. Schade. The network helps show where David S. Schade may publish in the future.

Co-authorship network of co-authors of David S. Schade

This figure shows the co-authorship network connecting the top 25 collaborators of David S. Schade. A scholar is included among the top collaborators of David S. Schade based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David S. Schade. David S. Schade is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Schade, David S., et al.. (2026). Ten reasons to treat all individuals with a positive coronary artery calcium score. The American Journal of Medicine.
2.
Schade, David S., et al.. (2025). Minimal methimazole exposure-induced fatal pancytopenia. BMJ Case Reports. 18(1). e261106–e261106.
3.
Schade, David S., et al.. (2023). Interpreting the Coronary Artery Calcium Score – Critical Information for the Practicing Physician. The American Journal of Medicine. 136(11). 1070–1075. 2 indexed citations
4.
Eaton, R. Philip, et al.. (2021). Finance Policy for Public Health Disease Prevention: Addressing the Number One Cause of Death in the Western World. World Journal of Cardiovascular Diseases. 11(12). 553–563. 1 indexed citations
5.
Schade, David S., et al.. (2021). Resolving the Egg and Cholesterol Intake Controversy: New Clinical Insights Into Cholesterol Regulation by the Liver and Intestine. Endocrine Practice. 28(1). 102–109. 9 indexed citations
6.
Bebu, Ionut, David S. Schade, Barbara H. Braffett, et al.. (2020). Risk Factors for First and Subsequent CVD Events in Type 1 Diabetes: The DCCT/EDIC Study. Diabetes Care. 43(4). 867–874. 63 indexed citations
7.
Bebu, Ionut, Barbara H. Braffett, David S. Schade, et al.. (2020). An Observational Study of the Equivalence of Age and Duration of Diabetes to Glycemic Control Relative to the Risk of Complications in the Combined Cohorts of the DCCT/EDIC Study. Diabetes Care. 43(10). 2478–2484. 18 indexed citations
8.
Schade, David S., et al.. (2020). Cholesterol Review: A Metabolically Important Molecule. Endocrine Practice. 26(12). 1514–1523. 172 indexed citations
9.
Schade, David S. & R. Philip Eaton. (2019). A Simplified Approach to Reducing Cardiovascular Risk. The Journal of Clinical Endocrinology & Metabolism. 104(12). 6033–6039. 8 indexed citations
10.
Budoff, Matthew J., Jye‐Yu C. Backlund, David A. Bluemke, et al.. (2019). The Association of Coronary Artery Calcification With Subsequent Incidence of Cardiovascular Disease in Type 1 Diabetes. JACC. Cardiovascular imaging. 12(7). 1341–1349. 54 indexed citations
11.
Schade, David S., Gayle M. Lorenzi, Barbara H. Braffett, et al.. (2018). Hearing Impairment and Type 1 Diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Cohort. Diabetes Care. 41(12). 2495–2501. 30 indexed citations
12.
Bouchonville, Matthew F., et al.. (2014). The Effectiveness and Risks of Programming an Insulin Pump to Counteract the Dawn Phenomenon in Type 1 Diabetes. Endocrine Practice. 1–25. 18 indexed citations
13.
Burge, Mark R., et al.. (2014). Is the Masked Continuous Glucose Monitoring System Clinically Useful for Predicting Hemoglobin A1C in Type 1 Diabetes?. Diabetes Technology & Therapeutics. 16(5). 292–297. 3 indexed citations
14.
Gutierrez, Absalon, et al.. (2013). Does Short-Term Vitamin C Reduce Cardiovascular Risk in Type 2 Diabetes?. Endocrine Practice. 19(5). 785–791. 11 indexed citations
15.
Robinson, I., et al.. (2006). Vitamin E in Humans: An Explanation of Clinical Trial Failure. Endocrine Practice. 12(5). 576–582. 72 indexed citations
16.
Carroll, Mary F. & David S. Schade. (2005). The Dawn Phenomenon Revisited: Implications for Diabetes Therapy. Endocrine Practice. 11(1). 55–64. 73 indexed citations
17.
Burge, Mark R., Amer Rassam, & David S. Schade. (1998). Lispro Insulin: Benefits and Limitations. Trends in Endocrinology and Metabolism. 9(8). 337–341. 3 indexed citations
18.
Krentz, Andrew J., Patrick J. Boyle, Linda MacDonald, & David S. Schade. (1994). Octreotide: A long-acting inhibitor of endogenous hormone secretion for human metabolic investigations. Metabolism. 43(1). 24–31. 38 indexed citations
19.
Melchionda, N., et al.. (1984). Recent advances in obesity and diabetes research. Raven Press eBooks. 7 indexed citations
20.
Schade, David S.. (1981). Diabetic coma, ketoacidotic and hyperosmolar. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by G. Perriello Breakdown of academic impact, for papers by Graydon S. Meneilly Breakdown of academic impact, for papers by Rudolf Prager Breakdown of academic impact, for papers by Robert Sherwin Breakdown of academic impact, for papers by A H Barnett Breakdown of academic impact, for papers by Marilyn Ader Breakdown of academic impact, for papers by Antonio E. Pontiroli Breakdown of academic impact, for papers by Annunziata Lapolla Breakdown of academic impact, for papers by Marc Rendell Breakdown of academic impact, for papers by Stephen D. Luzio
Rankless by CCL
2026